Discover the people, geography, and economy.
Get information on what Ontario can offer your business.
Watch videos that show how companies across industries thrive here.
Canada's largest chemical manufacturing sector
Ontario has the right environment for robotics companies to flourish
Canada’s top tourism market: 55% of all international visitors.
Photo by Centre for Commercialization of Regenerative Medicine
In the 55 years since Drs. James Till and Ernest McCulloch of the University of Toronto first demonstrated the existence of blood stem cells, the epicentre of pioneering developments in the research and commercialization of stem cell technologies and regenerative medicine remains planted firmly in Ontario. The province's ability to continue to develop and attract world-class talent and investment interest in this innovative field were boosted recently by two significant announcements: The opening of the Centre for Advanced Therapeutic Cell Technologies, the first such facility in the world to use a collaborative approach between research institutions and industry to solve cell therapy manufacturing challenges, and a pledge of support to the tune of $25 million in funding for the Ontario Institute for Regenerative Medicine (OIRM), from the Government of Ontario, heralded the start of 2016.
The Centre for Advanced Therapeutic Cell Technologies is made possible by $40 million in combined funding received from the Canadian government and GE Healthcare. The Prime Minister of Canada was on hand to officially announce funding for the facility, which is to be led by the Centre for Commercialization of Regenerative Medicine and located inside MaRS Discovery District in Toronto. It joins Johnson & Johnson's JLABS, the Ontario Genomics Institute, the University Health Network, Clinical Trials Ontario and other innovative organizations that call MaRS home.
We have built a strong industry consortium of nearly 50 companies to help drive a collaborative approach to realizing the potential of regenerative medicine. GE Healthcare already plays a leading role in that consortium and the company's deep knowledge of the bioprocessing industry, combined with its global scale and health care insights, makes it the ideal anchor partner for the new centre.
– Michael May, President and CEO of Centre for Commercialization of Regenerative Medicine (CCRM)
GE is investing $20M CAD to help companies bring promising cell therapies to market faster https://t.co/7Fi4pFu1Pz pic.twitter.com/gMCXJK2dJ4— GE Healthcare (@GEHealthcare) January 14, 2016
GE is investing $20M CAD to help companies bring promising cell therapies to market faster https://t.co/7Fi4pFu1Pz pic.twitter.com/gMCXJK2dJ4
According to CCRM's release, the centre will help accelerate the development and adoption of cell manufacturing technologies that will improve access to novel regenerative medicine-based therapies. Partners CCRM and GE Healthcare will welcome companies from the pharmaceutical, biotech and cell therapy sectors to bring the centre to life.
Meanwhile, funding from the province will support OIRM's 150 leading stem cell and regenerative medicine scientists, clinicians and engineers in their work to discover and develop treatments and therapies for people living with chronic diseases, such as cancer, multiple sclerosis and diabetes.
Learn more about the Centre for Commercialization of Regenerative Medicine
Discover Canada's largest centre of life sciences activity
January 28, 2016
Receive the latest news and updates from Invest in Ontario.
Sign up now
All figures are in Canadian dollars unless otherwise noted. Information is accurate at the time of publication.